The 2024 US Medical Eligibility Criteria for Contraceptive Use (US MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during ... Read more >

The 2024 US Selected Practice Recommendations for Contraceptive Use (US SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during ... Read more >

On March 4, 2024, the first daily over-the-counter oral contraceptive pill became available in the United States. This progestin-only pill (POP) is approved without a prescription for adolescents and adults to prevent pregnancy. The FDA did not approve this POP for menstrual suppression or other noncontraceptive indications. For both adults and adolescents, over-the-counter access to ... Read more >

The objective of this Clinical Recommendation is to review relevant literature and provide evidence-based recommendations for medication abortion between 14 0/7 and 27 6/7 weeks of gestation, with a focus on mifepristone-misoprostol and misoprostol-only regimens. We systematically reviewed PubMed articles published between 2008 and 2022 and reviewed reference lists of included articles to identify additional ... Read more >

Hemorrhage after abortion is rare, occurring in fewer than 1% of abortions, but associated morbidity may be significant. Although medication abortion is associated with more bleeding than procedural abortion, overall bleeding for the two methods is minimal and not clinically different. Hemorrhage can be caused by atony, coagulopathy, and abnormal placentation, as well as by ... Read more >